Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gliclazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gliclazide SCHEMBL1537023 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL291434 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL239075 | 0.99 | ALDH1A1 (0.97) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL6344915 | 0.94 | ALDH1A1 (0.88) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL30011556 | 0.93 | ALDH1A1 (0.86) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL6679802 | 0.90 | ALDH1A1 (0.80) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL1967443 | 0.88 | ALDH1A1 (0.77) | ALDH1A1LMNAAKR1C3GAATP53 | |
| SCHEMBL17309638 | 0.86 | ALDH1A1 (0.76) | ALDH1A1LMNAAKR1C3GAATP53 | |
| SCHEMBL17309632 | 0.85 | ALDH1A1 (0.74) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL22069924 | 0.85 | ALDH1A1 (0.72) | ALDH1A1LMNAAKR1C3GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 25097 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124282-A1 | DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2026-05-07 | — | — | US | claimed |
| EP-4734978-A2 | COMBINATION THERAPIES USING PSILOCYBIN | University of Padova (IT) | 2026-05-06 | — | — | EP | claimed |
| US-20260115210-A1 | METHOD FOR TREATING SUBJECTS SUFFERING FROM CENTRAL NERVOUS SYSTEM CONTUSIONS | REMEDY PHARMACEUTICALS, INC. (US) | 2026-04-30 | — | — | US | claimed |
| EP-4731239-A1 | ANALOGUES WITH IMPROVED PROPERTIES | Zealand Pharma A/S (DK) | 2026-04-29 | — | — | EP | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12611416-B2 | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema | REMEDY PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | claimed |
| EP-4717267-A1 | SYNERGISTIC COMBINATION FOR TREATING CANCER | FUNDACION UNIVERSITARIA SAN ANTONIO (UCAM) (ES) | 2026-04-01 | — | — | EP | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| EP-4714926-A1 | A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM WITH A TERTIARY AMINE | Hilti Aktiengesellschaft (LI) | 2026-03-25 | — | — | EP | claimed |
| EP-4714925-A1 | A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM | Hilti Aktiengesellschaft (LI) | 2026-03-25 | — | — | EP | claimed |
| CN-1194865-A | Threonate possessing of partial basicity and having basic chemical structure medicine in its molecule | GAO BINGYUAN (CN) | 1998-10-07 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| WO-1998036755-A1 | SULFONYLUREA-GLITAZONE SYNERGISTIC COMBINATIONS FOR DIABETES | WARNER LAMBERT COMPANY (US) | 1998-08-27 | — | — | WO | claimed |
| WO-1998011884-A1 | USE OF SIBUTRAMINE ANALOGUES TO PREVENT THE DEVELOPMENT OF DIABETES | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-03-26 | — | — | WO | claimed |
| CN-1166319-A | Compound hypoglycemic agent | XIAMEN PHARMACEUTICAL FACTORY (CN) | 1997-12-03 | — | — | CN | claimed |
| EP-0549433-A1 | Use of N'-substituted N-phenylsulfonylureas in the treatment of hypertension in insulin-resistant patients | ADIR ET COMPAGNIE (FR) | 1993-06-30 | — | — | EP | claimed |
| EP-0468392-A1 | Process for preparing pharmaceutical compositions having an increased active substance dissolution rate, and the compositions obtained | JAGOTEC AG (CH) | 1992-01-29 | — | — | EP | claimed |
| US-4708868-A | Oral anti-diabetic pharmaceutical forms and the preparation thereof | DR. KARL THOMAE GMBH (DE) | 1987-11-24 | — | — | US | claimed |
| US-4696815-A | Anti-diabetic pharmaceutical forms and the preparation thereof | DR. KARL THOMAE GMBH (DE) | 1987-09-29 | — | — | US | claimed |
| US-4056623-A | Methods of treating animals suffering from hyperlipidemia using certain N-phenyl sulphonyl-N'-(3-azabicycloalkyl) ureas | SCIENCE UNION ET CIE, SOCIETE FRANCAISE DE RECHERCHE MEDICALE (FR) | 1977-11-01 | — | — | US | claimed |